SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is facing intense post-earnings volatility as an unexpected CEO transition announcement overshadowed strong revenue and earnings results, fueling concerns about the firm's strategic direction in the AI era. While the community remains deeply divided between bargain hunters focusing on consistent fundamental growth and skeptics fearing that generative AI tools will erode the company's long-term competitive moat.

Trump For President

The TRUMP crypto token is currently trending as investors debate whether it acts as a genuine political expression or a high-risk pump-and-dump scheme. Community discussions are sharply divided, with supporters highlighting speculative potential and opposition pointing to its declining price action and intense political scrutiny.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is trending as market participants react to intensifying Middle East geopolitical tensions and surging oil prices, which are fueling concerns over inflation and potential economic headwinds. The community is sharply divided, with many traders debating the validity of 'buy-the-dip' strategies amid increased volatility and skepticism toward government-led market stabilization efforts.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne is facing intense volatility as the market debates its long-term growth prospects amid the broader software selloff and ongoing cybersecurity concerns. While investors are closely monitoring potential acquisition rumors and the firm's transition in financial leadership, the community remains divided over its valuation and the impact of AI on the cybersecurity competitive landscape.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is experiencing significant volatility driven by escalating geopolitical tensions in the Middle East and spiking oil prices, which have triggered broader market concerns about inflation and systemic financial stability. While some market participants are betting on a relief rally and Fed rate intervention, the community remains deeply divided, with active discussions focusing on algorithmic manipulation, high-risk oil supply chain disruptions, and the long-term impact of rising energy costs on tech-heavy valuations.

Kyivstar Group Ltd. engages in the telecommunications and digital business. It provides mobile, digital and fixed-line services. The company was founded in 1994 and is headquartered in Dubai, United Arab Emirates.

Kyivstar Group Ltd.

Kyivstar Group is attracting significant community attention as investors view it as a primary pure-play proxy for Ukraine's economic recovery and potential peace negotiations. Discussions are heavily focused on the company's resilient fundamentals, recent Starlink direct-to-cell integration, and the speculative upside tied to geopolitical developments.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is currently trending as investors weigh recent reports of in-house AI chip development against broader market skepticism regarding the sustainability of heavy AI-related capital expenditures. The community remains divided, with some traders viewing recent price volatility as a long-term buying opportunity in a fundamental powerhouse, while others express frustration over the stock's tendency to struggle with resistance levels and its sensitivity to negative geopolitical headlines.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate Inc. is garnering significant community attention as investors anticipate a major FDA milestone, with the company currently awaiting a crucial status update on its NDA submission. Discussions are heavily focused on the stock's low float, institutional accumulation, and the potential for a massive valuation shift driven by the upcoming U.S. patent and PDUFA catalysts.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community highlights its long-term presence in the Solana ecosystem, emphasizing its role as a joke-meta pioneer and its commitment to organic growth. Supporters are actively engaging in social media threads by sharing the token's ticker alongside other major crypto assets and celebrating consistent community vibes and collaborative energy.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Senseonics is currently the center of investor discussion following the official rollout of its Eversense 365 integrated with the Twiist automated insulin delivery system, a milestone many view as a pivotal step in expanding its competitive footprint. While supporters highlight this product integration as a long-term growth catalyst, the community remains deeply divided, with many retail investors expressing frustration over the stock's recent price volatility and ongoing concerns regarding the company's long-term leadership and commercial execution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FY2030 Earnings Forecast for Savara Issued By HC Wainwright

Savara Inc. (NASDAQ:SVRA - Free Report) - HC Wainwright issued their FY2030 earnings per share estimates for shares of Savara in a report released on Monday, March 9th. HC Wainwright analyst A. Fein...

Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Inc. (the Company) (Nasdaq: SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has received the Day 74 Letter from the FDA which...

Savara Announces Participation in 2026 Citizens Life Sciences Conference

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will participate in a...

Savara Inc. (NASDAQ:SVRA) Receives Average Recommendation of "Moderate Buy" from Analysts

Savara Inc. (NASDAQ:SVRA - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine research firms that are presently covering the company, Marketbeat reports...

Savara Highlights FDA Priority Review for Molbreevi as Aug. 22 PDUFA Date Nears

Savara (NASDAQ:SVRA) executives highlighted recent regulatory and commercial milestones for its lead program, molgramostim inhalation solution (Molbreevi), during a discussion at Oppenheimer's 36th...

<ul class="summary-bullets"><li>The FDA is expected to decide on the company’s application by Aug. 22, 2026.&nbsp;</li><li>Molbreevi had previously been granted FDA’s fast track, breakthrough therapy and orphan drug designations.&nbsp;</li><li>The company also plans to submit applications to Europe’s EMA and the UK’s MHRA seeking approval for Molbreevi by the end of the first quarter of 2026.</li></ul> Shares of Savara Inc. (SVRA) rallied over 3% after hours on Friday after the company announced that it has submitted an application to the U.S. Food and Drug Administration seeking approval for its experimental therapy Molbreevi.The company is <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20260220017435/en/Savara-Announces-the-U.S.-Food-and-Drug-Administration-FDA-Filed-the-MOLBREEVI-Biologics-License-Application-BLA-in-Autoimmune-Pulmonary-Alveolar-Proteinosis-Autoimmune-PAP">seeking</a> approval for Molbreevi to treat patients with Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP). The agency has granted the therapy priority review and is expected to decide on the application by Aug. 22, 2026.Molbreevi had previously been granted FDA’s fast track, breakthrough therapy and orphan drug designations.<h2 class="st-heading-2">About Autoimmune PAP</h2>Autoimmune PAP is a rare lung disease characterized by the abnormal build-up of surfactant, consisting of proteins and lipids, in the lung’s alveoli. While in a healthy lung surfactant is cleared, in autoimmune PAP it is left to accumulate causing impaired gas transfer, resulting in clinical symptoms of shortness of breath, often with cough and frequent fatigue.The company now plans to submit applications to the European Medicines Agency (EMA) and the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) seeking approval for Molbreevi by the end of the first quarter of 2026.“We believe the considerable body of data in the application demonstrates MOLBREEVI improves pulmonary gas transfer, quality of life, and the clinical symptoms associated with this rare and debilitating lung disease.” said CEO Matt Pauls.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SVRA rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<a href="https://stocktwits.com/symbol/SVRA">SVRA stock</a> has more than doubled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/sarepta-hits-fresh-hurdle-as-court-revives-patent-lawsuit-with-regenxbio-over-muscular-disorder-therapy/cZRNSgQR4xu">Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

SVRA Stock Rises After Hours As FDA Grants Priority Review For Lung Disorder Therapy

The company is seeking approval for Molbreevi to treat patients with Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP).

Equity

The company is seeking approval for Molbreevi to treat patients with Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP).


Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced the FDA has filed for review the BLA for MOLBREEVI as a therapy to...

GSA Capital Partners LLP Has $1.33 Million Stock Holdings in Savara Inc. $SVRA

GSA Capital Partners LLP trimmed its holdings in Savara Inc. (NASDAQ:SVRA - Free Report) by 47.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange...

Savara Eyes August PDUFA for MOLBREEVI as FDA BLA Filing Decision Nears, Execs Say at Summit

Savara (NASDAQ:SVRA) executives provided an update on the company's regulatory timeline, manufacturing changes, clinical evidence, and commercial preparations for MOLBREEVI during a presentation at...

Savara Announces New Employment Inducement Grant

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On February 10, 2026...

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

Current Price	$5.32
Prev Close	$5.53
Open	$5.41
Dividend Yield	0.00%
50-Day Moving Average	$5.71
Beta	1.05
Avg. Volume	1.65M
PE Ratio	-10.33

52-Week High	$7.01
52-Week Low	$1.89
Market Capitalization	$1.13B
EPS (Annual)	-$0.4838
Price to Book	10.13
Revenue Per Employee	$0.00

SVRA
Savara Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SVRA News

SVRASavara Inc